

# Hideaki Ijichi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3534896/hideaki-ijichi-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105  
papers

3,990  
citations

37  
h-index

60  
g-index

137  
ext. papers

4,484  
ext. citations

6.3  
avg, IF

4.84  
L-index

#	Paper	IF	Citations
105	Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma.. <i>British Journal of Anaesthesia</i> , <b>2022</b> ,	5.4	2
104	Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism. <i>Gut</i> , <b>2021</b> , 70, 1713-1723	19.2	10
103	ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 1020-1028	4	1
102	A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 605-613	4.3	2
101	Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosis. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 99	9.8	11
100	Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A prospective cohort study. <i>Clinical Nutrition</i> , <b>2021</b> , 40, 4792-4798	5.9	3
99	Inhibition of transforming growth factor- $\beta$ signaling in myeloid cells ameliorates aortic aneurysmal formation in Marfan syndrome. <i>PLoS ONE</i> , <b>2020</b> , 15, e0239908	3.7	1
98	Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects. <i>Pain</i> , <b>2020</b> , 161, 2909-2919	8	5
97	Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. <i>Scientific Reports</i> , <b>2020</b> , 10, 21194	4.9	7
96	Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis. <i>Cancer Genomics and Proteomics</i> , <b>2020</b> , 17, 695-705	3.3	6
95	Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms. <i>Gastroenterology</i> , <b>2020</b> , 158, 226-237.e5	13.3	80
94	Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment. <i>Oncogenesis</i> , <b>2019</b> , 8, 8	6.6	43
93	Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. <i>Pancreatology</i> , <b>2019</b> , 19, 695-698	3.8	4
92	Indirubin 3SOxime Inhibits Migration, Invasion, and Metastasis InVivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways. <i>Translational Oncology</i> , <b>2019</b> , 12, 1574-1582	4.9	11
91	Late-Evening Carbohydrate and Branched-Chain Amino Acid Snacks Improve the Nutritional Status of Patients Undergoing Hepatectomy Based on Bioelectrical Impedance Analysis of Body Composition. <i>Gastrointestinal Tumors</i> , <b>2019</b> , 6, 81-91	1.3	1
90	Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation. <i>Scientific Reports</i> , <b>2019</b> , 9, 18859	4.9	11
89	A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 338-344	4.3	5

88	Effect of home enteral nutrition after pancreaticoduodenectomy. <i>Nutrition</i> , <b>2019</b> , 60, 206-211	4.8	2
87	Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. <i>Scientific Reports</i> , <b>2018</b> , 8, 6150	4.9	13
86	Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1. <i>Cancer Science</i> , <b>2018</b> , 109, 3602-3610	6.9	11
85	Adhesive Interactions between Mononuclear Phagocytes and Intestinal Epithelium Perturb Normal Epithelial Differentiation and Serve as a Therapeutic Target in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 1219-1231	1.5	11
84	A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. <i>Medical Oncology</i> , <b>2018</b> , 35, 100	3.7	8
83	Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E3806-E3815	11.5	49
82	Prevalence of Pancreatic Cystic Lesions Is Associated With Diabetes Mellitus and Obesity: An Analysis of 5296 Individuals Who Underwent a Preventive Medical Examination. <i>Pancreas</i> , <b>2017</b> , 46, 801-805	3.6	25
81	Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. <i>Oncogene</i> , <b>2017</b> , 36, 6262-6271	9.2	31
80	A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. <i>Scientific Reports</i> , <b>2016</b> , 6, 23899	4.9	43
79	Satellite RNAs promote pancreatic oncogenic processes via the dysfunction of YBX1. <i>Nature Communications</i> , <b>2016</b> , 7, 13006	17.4	25
78	A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. <i>Journal of Gastroenterology</i> , <b>2016</b> , 51, 711-21	6.9	11
77	Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 61469-61484	3.3	49
76	No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer. <i>Anticancer Research</i> , <b>2016</b> , 36, 4965-70	2.3	3
75	Sharnin promotes hepatocellular carcinoma progression via transactivation of Versican expression. <i>Oncogenesis</i> , <b>2016</b> , 5, e277	6.6	16
74	TGF- $\beta$ Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota. <i>Journal of Immunology</i> , <b>2016</b> , 196, 4603-13	5.3	22
73	The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2015</b> , 141, 933-9	4.9	15
72	Pancreatic cancer with malignant ascites: clinical features and outcomes. <i>Pancreas</i> , <b>2015</b> , 44, 380-5	2.6	25
71	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1979	59.2	212

70	Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. <i>Journal of Gastrointestinal Cancer</i> , <b>2014</b> , 45, 307-11	1.6	17
69	Disease-specific mortality among patients with intraductal papillary mucinous neoplasm of the pancreas. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 486-91	6.9	12
68	Photoacoustic tomography of human hepatic malignancies using intraoperative indocyanine green fluorescence imaging. <i>PLoS ONE</i> , <b>2014</b> , 9, e112667	3.7	29
67	Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 1090-5	11.5	83
66	Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBP $\beta$ . <i>Carcinogenesis</i> , <b>2014</b> , 35, 2404-14	4.6	70
65	A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 911-5	3.5	7
64	Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. <i>Pancreas</i> , <b>2014</b> , 43, 1014-7	2.6	15
63	Which patients benefit from the inhibition of renin-angiotensin system in advanced pancreatic cancer? An exploratory analysis in 349 patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15216-e15216	2.2	
62	A phase 1 trial of GSL (gemcitabine, S-1, LV) combination therapy in advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 290-290	2.2	
61	Associations between K-ras mutation, smoking, and prognosis of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 298-298	2.2	
60	Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. <i>Journal of Gastroenterology</i> , <b>2013</b> , 48, 238-46	6.9	36
59	Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 85-92	3.5	19
58	A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 985-90	3.5	11
57	A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 1291-7	3.5	14
56	Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. <i>Pancreatology</i> , <b>2013</b> , 13, 285-9	3.8	14
55	A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1294-9	4.3	38
54	Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells. <i>Carcinogenesis</i> , <b>2013</b> , 34, 2380-8	4.6	38
53	Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. <i>Pancreas</i> , <b>2013</b> , 42, 687-91	2.6	24

52	Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. <i>Pancreas</i> , <b>2013</b> , 42, 202-8	2.6	47
51	Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. <i>Cancer Research</i> , <b>2013</b> , 73, 2221-34	10.1	39
50	Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer. <i>Cancer Science</i> , <b>2013</b> , 104, 337-44	6.9	33
49	A retrospective analysis of early CA19-9 progression in salvage-chemotherapy for refractory pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e15146-e15146	2.2	
48	Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. <i>Cancer Science</i> , <b>2012</b> , 103, 670-6	6.9	212
47	Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. <i>Cancer Science</i> , <b>2012</b> , 103, 1489-92	6.9	29
46	Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. <i>Journal of Gastroenterology</i> , <b>2012</b> , 47, 203-13	6.9	63
45	Engineering fibrotic tissue in pancreatic cancer: a novel three-dimensional model to investigate nanoparticle delivery. <i>Biochemical and Biophysical Research Communications</i> , <b>2012</b> , 419, 32-7	3.4	37
44	Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2173-83	12.9	48
43	3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway. <i>Laboratory Investigation</i> , <b>2012</b> , 92, 1161-70	5.9	14
42	Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer. <i>Onc Immunology</i> , <b>2012</b> , 1, 569-571	7.2	15
41	Abstract 4383: Targeting tumor microenvironment with gemcitabine is useful for the treatment of pancreatic ductal adenocarcinoma <b>2012</b> ,		11
40	Effect of non-anticancer drugs on prognosis of pancreatic cancer (PaC) receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 309-309	2.2	
39	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1400-8	13.4	47
38	Reduced expression of RAS protein activator like-1 in gastric cancer. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 1293-302	7.5	18
37	Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. <i>Gut</i> , <b>2011</b> , 60, 1249-53	19.2	47
36	Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 4106-17	15.9	191
35	Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. <i>World Journal of Clinical Oncology</i> , <b>2011</b> , 2, 158-63	2.5	19

34	Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. <i>World Journal of Clinical Oncology</i> , <b>2011</b> , 2, 195-202	2.5	21
33	Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 1644-8	8.7	121
32	Identification of a suppressive mechanism for Hedgehog signaling through a novel interaction of Gli with 14-3-3. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 4185-4194	5.4	30
31	Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. <i>Japanese Journal of Clinical Oncology</i> , <b>2010</b> , 40, 774-80	2.8	33
30	Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses. <i>Gastroenterology</i> , <b>2010</b> , 138, 1055-67.e1-4	13.3	49
29	Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 394, 1042-6	3.4	54
28	Impact of S-1 on the survival of patients with advanced pancreatic cancer. <i>Pancreas</i> , <b>2010</b> , 39, 989-93	2.6	27
27	Genetically-engineered mouse pancreatic cancer models. <i>Suizo</i> , <b>2010</b> , 25, 28-34	0.1	
26	A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. <i>Oncology</i> , <b>2009</b> , 77, 300-3	3.6	25
25	Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer. <i>Molecular Carcinogenesis</i> , <b>2009</b> , 48, 703-12	5	90
24	Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. <i>Gastroenterology</i> , <b>2009</b> , 136, 206-16	13.3	71
23	Runx3 interacts with DNA repair protein Ku70. <i>Experimental Cell Research</i> , <b>2007</b> , 313, 3251-60	4.2	14
22	Smad4 is essential for down-regulation of E-cadherin induced by TGF-beta in pancreatic cancer cell line PANC-1. <i>Journal of Biochemistry</i> , <b>2007</b> , 141, 345-51	3.1	33
21	TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 2237-46	7.5	13
20	Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. <i>Genes and Development</i> , <b>2006</b> , 20, 3147-60	12.6	285
19	The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. <i>Oncogene</i> , <b>2006</b> , 25, 633-42	9.2	77
18	Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta. <i>Oncogene</i> , <b>2005</b> , 24, 662-71	9.2	69
17	Reduced p38 mitogen-activated protein kinase in donor grafts accelerates acute intestinal graft-versus-host disease in mice. <i>European Journal of Immunology</i> , <b>2005</b> , 35, 2210-21	6.1	3

16	p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. <i>Cancer Research</i> , <b>2005</b> , 65, 10822-9	10.1	77
15	Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components. <i>Nucleic Acids Research</i> , <b>2005</b> , 33, e131	20.1	40
14	Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. <i>Cancer Research</i> , <b>2005</b> , 65, 5864-71	10.1	162
13	Cancer-derived VEGF plays no role in malignant ascites formation in the mouse. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 5455-9	5.6	5
12	Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. <i>Cancer Research</i> , <b>2004</b> , 64, 3428-35	10.1	61
11	Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta. <i>Oncogene</i> , <b>2004</b> , 23, 1043-51	9.2	69
10	Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis. <i>Cancer Genetics and Cytogenetics</i> , <b>2004</b> , 149, 68-71		15
9	Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. <i>Hepatology</i> , <b>2004</b> , 40, 243-51	11.2	104
8	Proteomic analysis of the TGF-beta signaling pathway in pancreatic carcinoma cells using stable RNA interference to silence Smad4 expression. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 318, 289-96	3.4	32
7	Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 318, 461-9	3.4	78
6	Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. <i>Cancer Research</i> , <b>2003</b> , 63, 8132-7	10.1	106
5	Analysis of the beta-catenin/T cell factor signaling pathway in 36 gastrointestinal and liver cancer cells. <i>Japanese Journal of Cancer Research</i> , <b>2002</b> , 93, 1213-20		45
4	False positive uptake of metaiodobenzylguanidine in hepatocellular carcinoma. <i>British Journal of Radiology</i> , <b>2002</b> , 75, 548-51	3.4	12
3	Frameshift mutations at mononucleotide repeats in RAD50 recombinational DNA repair gene in colorectal cancers with microsatellite instability. <i>Japanese Journal of Cancer Research</i> , <b>2001</b> , 92, 587-91		20
2	Systematic analysis of the TGF-beta-Smad signaling pathway in gastrointestinal cancer cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2001</b> , 289, 350-7	3.4	56
1	Fuel economy of multigrade gear lubricants. <i>Industrial Lubrication and Tribology</i> , <b>2000</b> , 52, 165-173	1.3	12